The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching

The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching

Abstract Purpose Whether the addition of tislelizumab to gemcitabine and cisplatin (GC) chemotherapy increases the incidence of myelosuppression has not been well established. This study identified the risk factors for the development of myelosuppression in patients with urothelial carcinoma (UC) af...

Full description

Bibliographic Details
Main Authors: Zhimin Gao, Nienie Qi, Xu Qin, Zhen Li, Gang Li, Zewei Wang, Junqi Wang, Rumin Wen, Hailong Li
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Cancer Medicine
Subjects:
cisplatin
gemcitabine
myelosuppression
risk factors
tislelizumab
urothelial carcinoma
Online Access:https://doi.org/10.1002/cam4.6807

Similar Items

Similar Items